TrialCancer discovery2023

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.

Tina Cascone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.